Variation in responses to incretin therapy: Modifiable and non-modifiable factors (2023)
Attributed to:
Targeting GLP-1 receptor trafficking to improve therapies for type 2 diabetes
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3389/fmolb.2023.1170181
PubMed Identifier: 37091864
Publication URI: http://europepmc.org/abstract/MED/37091864
Type: Journal Article/Review
Parent Publication: Frontiers in Molecular Biosciences